Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling.

Pocobelli G, Chubak J, Hanson N, Drescher C, Resta R, Urban N, Buist DS.

Gynecol Oncol. 2012 Aug;126(2):229-35. doi: 10.1016/j.ygyno.2012.04.046. Epub 2012 May 4.

2.

Systematic review of management options for women with a hereditary predisposition to ovarian cancer.

Rosen B, Kwon J, Fung Kee Fung M, Gagliardi A, Chambers A; Cancer Care Ontario's Practice Guidelines Initiative Gynecology Cancer Disease Site Group.

Gynecol Oncol. 2004 May;93(2):280-6. Review.

PMID:
15099934
3.

Prophylactic oophorectomy: a continuing controversy.

Fong YF, Lim FK, Arulkumaran S.

Obstet Gynecol Surv. 1998 Aug;53(8):493-9. Review.

PMID:
9702789
4.

Prophylactic oophorectomy in women at increased cancer risk.

Domchek SM, Rebbeck TR.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. Review.

PMID:
17218848
5.

Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A; Society of Gynecologic Oncologists Clinical Practice Committee.

Obstet Gynecol. 2010 Sep;116(3):733-43. doi: 10.1097/AOG.0b013e3181ec5fc1. Review.

PMID:
20733460
6.

Prophylactic oophorectomy: why and when?

Lane G.

J Br Menopause Soc. 2003 Dec;9(4):156-60. Review.

PMID:
15107258
7.

Genetic susceptibility testing and prophylactic oophorectomy.

Berchuck A, Carney ME, Futreal PA.

Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):159-64. Review.

PMID:
10206409
8.

Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.

Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.

Ann Intern Med. 2014 Feb 18;160(4):255-66. Review.

PMID:
24366442
9.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force.

Ann Intern Med. 2005 Sep 6;143(5):362-79. Review. Erratum in: Ann Intern Med. 2005 Oct 4;143(7):547.

PMID:
16144895
10.

Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.

S√łgaard M, Kjaer SK, Gayther S.

Acta Obstet Gynecol Scand. 2006;85(1):93-105. Review.

PMID:
16521688
11.

Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.

Roukos DH, Briasoulis E.

Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. Review.

PMID:
17898808
12.

Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.

Olopade OI, Artioli G.

Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9. Review.

PMID:
14984481
13.

Supplemental Content

Support Center